Komori
Medipal Holdings (7459) · PolicyRestated

Social infrastructure function supporting the stable supply of medical and daily-use products

First written in FY2016. 19 of 22 entries say "Restated". Latest entry: FY2026.

22entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2021RestatedFY2022-Q2 – FY2022AdvancedFY20242016: 320162017: 220172018: 420182019: 220192020: 320202021: 320212022: 220222023: 020232024: 120242025: 020252026: 22026
Same theme, other companies

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「We handle pharmaceuticals for medical use, medical devices, clinical laboratory reagents, daily-use products, cosmetics, food-processing raw materials and other products that are all indispensable to supporting people’s lives and healthy livelihoods. We recognize that, as a company responsible for social infrastructure, building logistics functions and distribution networks capable of delivering these products without interruption, both under normal conditions and in emergencies, is an important responsibility.」

    The company continues to maintain its fundamental stance of providing stable supplies of products essential to people’s lives and livelihoods and operating the logistics network as social infrastructure.
  2. 2026-05-25RestatedGeneral Meetings of Shareholders

    「We recognize that, as a company responsible for social infrastructure, it is an important responsibility to build logistics functions and distribution networks capable of delivering without interruption in both normal and emergency situations. Based on this fundamental position, the Group has formulated a BCP (business continuity plan) and is working to further advance its logistics platform.」

    The Company continues to regard stable supply in both normal and emergency situations and its BCP as responsibilities arising from its role as social infrastructure.
  3. FY2024AdvancedAnnual report

    「Based on this fundamental stance, our Group has formulated a BCP (business continuity plan), and following the Noto Peninsula Earthquake that occurred on 1 January 2024, we worked to ensure a stable supply of necessary products in the affected areas.」

    Regarding the policy of providing stable supply as social infrastructure, the filing described the company’s efforts to supply products to affected areas following the Noto Peninsula Earthquake.
  4. FY2022RestatedAnnual report

    「The products handled by each business of our Group are indispensable to safe and secure living, and a stable supply is required at all times, both under normal conditions and in emergencies. Although the end of the COVID-19 pandemic remains difficult to foresee, we will continue to fulfill our role as social infrastructure.」

    The company reaffirmed its policy of continuing to provide a stable supply of pharmaceuticals, daily-use products and other items as social infrastructure even though the end of the pandemic remains difficult to foresee.
  5. FY2022-Q3RestatedAnnual report

    「Against this backdrop, as a business operator handling pharmaceuticals, daily-use products and other items, our Group is required to maintain business continuity. Guided by our unchanged mission of ensuring a stable supply of necessary products, we are making every effort to support people’s lives and livelihoods.」

    Even amid the emergence of COVID-19 variants, the company continues to regard the stable supply of necessary products as its unchanged mission.
  6. FY2022-Q2RestatedAnnual report

    「Against this backdrop, as a business operator handling pharmaceuticals, daily-use products and other items, our Group is required to maintain business continuity. Guided by our unchanged mission of ensuring a stable supply of necessary products, we are making every effort to support people’s lives and livelihoods.」

    Even as the impact of the COVID-19 pandemic continues, the company continues to regard the stable supply of pharmaceuticals and daily-use products as its unchanged mission.
  7. FY2022-Q1AdvancedAnnual report

    「Our high-quality, high-function ALC facilities, equipped with disaster countermeasures, provide a logistics platform capable of handling all temperature ranges, including ultra-low temperatures, to deliver regenerative medicine products and other products requiring strict temperature control safely and securely. These technologies and expertise are also being used to store and deliver the COVID-19 vaccines handled by our Group.」

    Regarding logistics functions as social infrastructure, the filing stated that technologies and expertise covering all temperature ranges are also being used in the actual storage and delivery of COVID-19 vaccines.
  8. FY2021RestatedAnnual report

    「Although the end of the COVID-19 pandemic remains difficult to foresee, we will continue to fulfill our role as social infrastructure.」

    The company has reaffirmed its policy of continuing to provide a stable supply of pharmaceuticals, daily-use products and other items as social infrastructure even during the pandemic.
  9. FY2021-Q2RestatedAnnual report

    「Against this backdrop, as a business operator handling pharmaceuticals and daily-use products, our Group is required to maintain business continuity. Guided by our unchanged mission of ensuring a stable supply of products at all times, we are making every effort to support people’s lives and livelihoods.」

    Even amid the COVID-19 pandemic, the company continues to regard the stable supply of pharmaceuticals and daily-use products as its mission of supporting people’s lives and livelihoods.
  10. FY2021-Q1RestatedAnnual report

    「Against this backdrop, as a business operator handling pharmaceuticals and daily-use products, our Group is required to maintain business continuity. With the mission of ensuring a stable supply of products at all times, we are making every effort to support people’s lives and livelihoods.」

    Even amid the COVID-19 pandemic, the company continues to pursue a policy of positioning the stable supply of pharmaceuticals and daily-use products as its mission as a business operator.
  11. FY2020-Q3RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting safe and secure healthcare and optimizing the entire supply chain from pharmaceutical companies to patients.
  12. FY2020-Q2RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting healthcare and optimizing and improving the efficiency of the entire supply chain.
  13. FY2019-Q3RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting safe and secure healthcare and optimizing and improving the efficiency of the entire supply chain.
  14. FY2019-Q2RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting safe and secure healthcare and optimizing and improving the efficiency of the entire supply chain.
  15. FY2019-Q1RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting healthcare and optimizing and improving the efficiency of the entire supply chain.
  16. FY2018RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting healthcare and optimizing and improving the efficiency of the entire supply chain.
  17. FY2018-Q3RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting safe and secure healthcare and optimizing and improving the efficiency of the entire supply chain.
  18. FY2018-Q2RestatedAnnual report

    「As a wholesaler supporting safe and secure healthcare, this business is actively undertaking a range of initiatives and investments to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as a wholesaler supporting safe and secure healthcare and as social infrastructure that optimizes and improves the efficiency of the entire supply chain.
  19. FY2017-Q3RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting healthcare and optimizing the entire supply chain from pharmaceutical companies to patients.
  20. FY2017-Q2RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting healthcare and optimizing the entire supply chain from pharmaceutical companies to patients.
  21. FY2017-Q1RestatedAnnual report

    「As social infrastructure supporting safe and secure healthcare, this business undertakes a range of initiatives to maximize the functions of a wholesaler in order to optimize and improve the efficiency of the entire supply chain, from pharmaceutical companies to patients.」

    The business continues to be positioned as social infrastructure supporting healthcare and optimizing and improving the efficiency of the entire supply chain.
  22. FY2016First statedAnnual report

    「The products handled by each business of our Group are indispensable to safe and secure living, and a stable supply is required at all times, both under normal conditions and in emergencies. We will continue to grow as part of the social infrastructure that fulfills this role.」

    The distribution of pharmaceuticals, cosmetics, daily-use products and veterinary pharmaceuticals is positioned as social infrastructure that must be maintained under both normal conditions and in emergencies.
Moved together

"Revenue Diversification through Strengthening Logistics and Sales Functions and Creating New Businesses" moved the same way as this thread, in the same document, in 2 of its 22 moves.

22222★12345
  1. ★This thread
  2. 1Revenue Diversification through Strengthening Logistics and Sales Functions and Creating New Businesses2×
  3. 2Risk Management Framework Based on Rules, Training, Manuals and Internal Audit2×
  4. 3Drug Discovery and U.S. Expansion Through a Business and Capital Alliance with JCR Pharmaceuticals2×
  5. 4Building PALTAC’s sales-driving model using in-store information2×
  6. 5Patients Refraining from Seeking Medical Care and Declining Sales of Prescription Pharmaceuticals Due to the Spread of COVID-192×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Medipal Holdings's next results are scheduled for 2026-11-05. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-05-25: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Social infrastructure function supporting the stable supply of medical and daily-use products | MEDIPAL HOLDINGS CORPORATION (7459) | Komori